JP2020530493A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530493A5 JP2020530493A5 JP2020530423A JP2020530423A JP2020530493A5 JP 2020530493 A5 JP2020530493 A5 JP 2020530493A5 JP 2020530423 A JP2020530423 A JP 2020530423A JP 2020530423 A JP2020530423 A JP 2020530423A JP 2020530493 A5 JP2020530493 A5 JP 2020530493A5
- Authority
- JP
- Japan
- Prior art keywords
- bacterial strain
- pharmaceutical composition
- bacterial
- feces
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001580 bacterial effect Effects 0.000 claims description 178
- 239000008194 pharmaceutical composition Substances 0.000 claims description 91
- 239000000203 mixture Substances 0.000 claims description 80
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 55
- 241000894006 Bacteria Species 0.000 claims description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 10
- 210000000936 intestine Anatomy 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000002550 fecal effect Effects 0.000 claims description 5
- 210000003608 fece Anatomy 0.000 claims 11
- 150000004666 short chain fatty acids Chemical group 0.000 claims 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000000813 microbial effect Effects 0.000 claims 4
- 230000003248 secreting effect Effects 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 241000701474 Alistipes Species 0.000 claims 2
- 241000606125 Bacteroides Species 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 241000186394 Eubacterium Species 0.000 claims 2
- 241001608234 Faecalibacterium Species 0.000 claims 2
- 241000785902 Odoribacter Species 0.000 claims 2
- 241000605947 Roseburia Species 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 2
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 235000011054 acetic acid Nutrition 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 229940005605 valeric acid Drugs 0.000 claims 1
- 241000607142 Salmonella Species 0.000 description 44
- 241000193403 Clostridium Species 0.000 description 36
- 244000052769 pathogen Species 0.000 description 19
- 241000588724 Escherichia coli Species 0.000 description 14
- 238000011319 anticancer therapy Methods 0.000 description 14
- 230000003115 biocidal effect Effects 0.000 description 14
- 241000192142 Proteobacteria Species 0.000 description 12
- 241000589876 Campylobacter Species 0.000 description 8
- 241000194033 Enterococcus Species 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 108090000204 Dipeptidase 1 Proteins 0.000 description 6
- 241000588921 Enterobacteriaceae Species 0.000 description 6
- 241000607768 Shigella Species 0.000 description 6
- 102000006635 beta-lactamase Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002626 targeted therapy Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 241000606161 Chlamydia Species 0.000 description 4
- 241000305071 Enterobacterales Species 0.000 description 4
- 241000588722 Escherichia Species 0.000 description 4
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 4
- 241000589989 Helicobacter Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000186359 Mycobacterium Species 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- 241000607598 Vibrio Species 0.000 description 4
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 4
- 229940124307 fluoroquinolone Drugs 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 4
- 229960003165 vancomycin Drugs 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- 241000607528 Aeromonas hydrophila Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000193755 Bacillus cereus Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000589968 Borrelia Species 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- 241001453380 Burkholderia Species 0.000 description 2
- 241000589874 Campylobacter fetus Species 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 241000589601 Francisella Species 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 241001503405 Leptosira Species 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 241000588771 Morganella <proteobacterium> Species 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 241000984031 Orientia Species 0.000 description 2
- 241000607000 Plesiomonas Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000607265 Vibrio vulnificus Species 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 241000607447 Yersinia enterocolitica Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 208000037815 bloodstream infection Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940098232 yersinia enterocolitica Drugs 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010064687 Device related infection Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542033P | 2017-08-07 | 2017-08-07 | |
| US62/542,033 | 2017-08-07 | ||
| PCT/US2018/045592 WO2019032572A1 (en) | 2017-08-07 | 2018-08-07 | COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530493A JP2020530493A (ja) | 2020-10-22 |
| JP2020530493A5 true JP2020530493A5 (https=) | 2021-09-24 |
Family
ID=65272652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530423A Pending JP2020530493A (ja) | 2017-08-07 | 2018-08-07 | 腸内の抗生物質耐性菌を除菌するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200093870A1 (https=) |
| EP (1) | EP3665181A4 (https=) |
| JP (1) | JP2020530493A (https=) |
| KR (1) | KR20200037851A (https=) |
| CN (1) | CN111328331A (https=) |
| AU (1) | AU2018313765A1 (https=) |
| CA (1) | CA3072029A1 (https=) |
| WO (1) | WO2019032572A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| ES2993669T3 (en) | 2011-12-01 | 2025-01-03 | Univ Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| JP2020530494A (ja) | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド． | 健康な腸バリアを維持及び回復するための組成物及び方法 |
| UY37939A (es) * | 2017-10-18 | 2019-04-30 | Ascus Biosciences Inc | Aumento de la producción de aves de corral mediante la administración de un bioensamblaje sintético de microbios o cepas purificadas de los mismos |
| EP3773645A4 (en) | 2018-04-10 | 2021-11-24 | Siolta Therapeutics, Inc. | MICROBIAL CONSORTIA |
| BR112021012118A2 (pt) * | 2018-12-19 | 2021-09-08 | Healthy Cow Corporation | Composição probiótica em forma de gel, produto probiótico pronto para uso, kit, sistema, e, métodos para introduzir uma ou mais cepas de bactérias à vagina de um animal não humano, para tratar uma infecção uterina ou diminuir o risco de contrair uma infecção uterina em um animal não humano e para promover o estabelecimento ou manutenção de um microbioma vaginal saudável em um animal não humano |
| PH12021553137A1 (en) | 2019-07-19 | 2022-07-25 | Finch Therapeutics Holdings Llc | Methods and products for treatment of gastrointestinal disorders |
| US20220339212A1 (en) * | 2019-08-28 | 2022-10-27 | Xbiome Inc. | Compositions comprising bacterial species and methods related thereto |
| JP2022548785A (ja) | 2019-09-24 | 2022-11-21 | プロラクタ バイオサイエンス，インコーポレイテッド | 炎症性疾患及び免疫疾患の治療のための組成物及び方法 |
| CN120732903A (zh) | 2019-10-07 | 2025-10-03 | 谢尔塔治疗公司 | 治疗性药物组合物 |
| GB201915144D0 (en) * | 2019-10-18 | 2019-12-04 | Multigerm Uk Entpr Ltd | Method of promoting SCFA production by gut microbiota |
| CN115279382A (zh) * | 2019-10-18 | 2022-11-01 | 芬奇治疗控股有限责任公司 | 用于向受试者递送细菌代谢物的组合物和方法 |
| EP3838281A1 (en) * | 2019-12-20 | 2021-06-23 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| WO2021231804A2 (en) * | 2020-05-13 | 2021-11-18 | President And Fellows Of Harvard College | Methods and compositions for suppressing inflammation induced by gut microbes |
| GB202007452D0 (en) | 2020-05-19 | 2020-07-01 | Microbiotica Ltd | Threrapeutic bacterial composition |
| KR20230088680A (ko) | 2020-08-14 | 2023-06-20 | 프롤랙타 바이오사이언스, 인코포레이티드 | 박테리아 요법에 사용하기 위한 인간 모유 올리고당 조성물 |
| WO2022050082A1 (ja) * | 2020-09-01 | 2022-03-10 | 国立大学法人東北大学 | 乳汁中のＩｇＡ抗体含有量の増加剤 |
| CA3202362A1 (en) * | 2020-09-30 | 2022-04-07 | National Cancer Center | Enhancement of antitumor effect of immune checkpoint inhibitor through administration of intestinal ruminococcaceae bacterium |
| WO2022115646A1 (en) * | 2020-11-25 | 2022-06-02 | Seres Therapeutics, Inc. | Designed bacterial compositions for treating graft-versus-host-disease |
| US20230149483A1 (en) * | 2021-11-12 | 2023-05-18 | Iowa State University Research Foundation, Inc. | Short-chain fatty acid use to mitigate antimicrobial resistance and virulence gene transfer in the gut |
| WO2023100989A1 (ja) * | 2021-12-02 | 2023-06-08 | 国立大学法人東北大学 | 下痢治療剤および牛の下痢治療方法 |
| KR102780901B1 (ko) * | 2022-11-09 | 2025-03-17 | 주식회사 굿바이옴텍 | 베타-락탐계 항생제 내성 유전자 ｂｌａＣＴＸ－Ｍ－２２９ 및 퀴놀론계 항생제 내성 유전자 ｑｎｒＳ를 갖는 신규한 다제내성 대장균 균주 및 이의 용도 |
| CN116747227B (zh) * | 2023-08-12 | 2025-07-25 | 杭州市第一人民医院 | 泊马度胺在制备抗细菌感染药物中的应用 |
| WO2025093780A1 (en) * | 2023-11-05 | 2025-05-08 | Human Biome Institute S.A. | The concept of drugs made with the gut microbiota and its components and the method of their administration to obtain effective therapeutic effects |
| WO2025093778A1 (en) | 2023-11-05 | 2025-05-08 | Human Biome Institute S.A. | Functional compositions and methods of use thereof in eradication and/or decolonization of antibiotic-resistant bacteria and restoration of healthy microbiota |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6727061B2 (en) * | 1997-02-20 | 2004-04-27 | Cabtec, Inc. | Methods for identifying species or Shigella and E. coli using operon sequence analysis |
| JP2003516151A (ja) * | 1999-11-29 | 2003-05-13 | エイブイアイ バイオファーマ， インコーポレイテッド | 細菌１６Ｓおよび２３ＳｒＲＮＡに標的化された、荷電していないアンチセンスオリゴヌクレオチド、ならびにその使用 |
| US9968638B2 (en) * | 2011-03-09 | 2018-05-15 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| ES2993669T3 (en) * | 2011-12-01 | 2025-01-03 | Univ Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| US8921335B2 (en) * | 2012-01-31 | 2014-12-30 | The Regents Of The University Of California | Oral delivery of nucleic acid-based gene interfering agents by Salmonella |
| WO2014145958A2 (en) * | 2013-03-15 | 2014-09-18 | Seres Health, Inc. | Network-based microbial compositions and methods |
| KR102099503B1 (ko) * | 2013-06-05 | 2020-04-09 | 리바이오틱스, 인코퍼레이티드 | 미생물상 복원 요법(mrt) 조성물 |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| GB201519088D0 (en) * | 2015-10-28 | 2015-12-09 | Metabogen Ab | The use of bacteria formulations |
| JP2020530494A (ja) * | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド． | 健康な腸バリアを維持及び回復するための組成物及び方法 |
-
2018
- 2018-08-07 AU AU2018313765A patent/AU2018313765A1/en not_active Abandoned
- 2018-08-07 EP EP18843326.2A patent/EP3665181A4/en not_active Withdrawn
- 2018-08-07 CA CA3072029A patent/CA3072029A1/en active Pending
- 2018-08-07 WO PCT/US2018/045592 patent/WO2019032572A1/en not_active Ceased
- 2018-08-07 CN CN201880064759.2A patent/CN111328331A/zh active Pending
- 2018-08-07 KR KR1020207006802A patent/KR20200037851A/ko not_active Ceased
- 2018-08-07 JP JP2020530423A patent/JP2020530493A/ja active Pending
-
2019
- 2019-12-09 US US16/707,277 patent/US20200093870A1/en not_active Abandoned
-
2024
- 2024-02-28 US US18/590,022 patent/US20240307460A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530493A5 (https=) | ||
| AU2010339573B2 (en) | Compositions and method for treatment and prophylaxis of inflammatory bowel disease | |
| US20210106629A1 (en) | Compositions and Methods for Treating Inflammatory Bowel Diseases (IBDs) and Other Disorders | |
| Trop | Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease | |
| Tsilika et al. | A four-probiotic preparation for ventilator-associated pneumonia in multi-trauma patients: results of a randomized clinical trial | |
| Alexandre et al. | Probiotics: a new way to fight bacterial pulmonary infections? | |
| JP2009537547A (ja) | 生物学的治療組成物およびその使用 | |
| WO2012142605A1 (en) | Rapid recolonization deployment agent | |
| JP2019502724A (ja) | 腸内細菌叢を調節するための治療 | |
| JP2023550652A5 (https=) | ||
| Qasemi et al. | The power of probiotics to combat urinary tract infections: A comprehensive review | |
| Gionchetti et al. | Probiotics for the treatment of postoperative complications following intestinal surgery | |
| Faubion et al. | Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad | |
| WO2014011564A2 (en) | Compositions and method for treatment and prophylaxis of inflammatory bowel disease | |
| WO2014011233A1 (en) | Compositions and method for treatment and prophylaxis of inflammatory bowel disease | |
| Khan et al. | pylori Infection in human Gastrointestinal Cancer Diagnosis and Treatment Control: A review | |
| US11529375B2 (en) | Compositions and methods for treating diverticulitis and related disorders | |
| Fakayode | Correlation Between Reactive Oxygen Species and Synbiotics for Effective | |
| Boian | Local preoperative therapeutic actions in Hirschsprungs disease in newborns and infants | |
| EA050195B1 (ru) | Лечение микробного дисбиоза | |
| Guercini et al. | 97: Long Lasting Therapy for Recurrent Urinary Tract Infections in Women | |
| Gionchetti et al. | Probiotics in IBD: A Critical Review | |
| Burch | Understanding the rationale and use of probiotics in the treatment of IBD | |
| Kroeker et al. | Probiotics in Pouchitis and Ulcerative Colitis | |
| Lima et al. | eBook on Inflammatory Bowel Disease |